Loading clinical trials...
Loading clinical trials...
Phase 3 Study of Metformin in Adults With Type 1 Diabetes
The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.
Age
40 - No limit years
Sex
ALL
Healthy Volunteers
No
Royal Melbourne Hospital
Melbourne, Australia
St Vincent's Hospital
Melbourne, Australia
Royal Prince Albert Hospital
Sydney, Australia
St Joseph's Health Care
London, Ontario, Canada
Ottawa Hospital Riverside Campus
Ottawa, Canada
Steno Diabetes Centre
Gentofte Municipality, Denmark
Maastricht University Medical Centre
Maastricht, Netherlands
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Ayr Hospital
Ayr, United Kingdom
University Hospitals Bristol
Bristol, United Kingdom
Start Date
December 1, 2011
Primary Completion Date
March 19, 2017
Completion Date
April 18, 2017
Last Updated
June 19, 2019
493
ACTUAL participants
Metformin
DRUG
Placebo
DRUG
Lead Sponsor
University of Glasgow
Collaborators
NCT04786262
NCT06748963
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06325202